To develop accurate and representative reimbursement of costs, the National Tariff needs to take account of costs disproportionately borne by activity in a small number of providers. The National Tariff separates payment for particular high cost drugs, chemotherapy and high cost devices to achieve this.
In order to keep reimbursement current, we would welcome nominations for new drugs, and devices that should be separately reimbursed through local negotiation, rather than through National Tariff prices.
Similarly, we want to ensure that the chemotherapy regimens published list, in order to necessitate coding, reporting and costing of chemotherapy regimens in the NHS in England, remains current.
Please note that the deadline for nominations for Drugs and Devices for consideration in the 2015/16 National Tariff is the 31st January 2014, to allow time for consideration and the relevant impacts to be processed. Submissions received after this date will be considered for the 2016/17 National Tariff.
More detail on each of these areas is available through the links below.